The invention relates to compounds in the treatment or prevention of disorders associated with Lamin A and/or Lamin C depletion or LMNA mutations, such as laminopathy, premature ageing disorders, normal ageing and cancer (such as a cancer characterised by low levels of LMNA expression).

The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such as lung disease (e.g., idiopathic pulmonary fibrosis), kidney disease (e.g., chronic kidney disease), or hepatic disease (e.g., non-alcoholic steatohepatitis and portal hypertension).

##STR00001##

The present application relates to the technical field of organic electroluminescent materials, and provides a nitrogen-containing compound, an organic electroluminescent device comprising same, and an electronic apparatus. The nitrogen-containing compound of the present application comprises a parent nucleus structure of a benzophenoxazole/thiazole group. When the nitrogen-containing compound is used as a host material for an emission layer of the organic electroluminescent device, the luminous efficiency and service life of the device can be remarkably improved.

An acid diffusion control agent includes a compound represented by a formula (1), a compound represented by a formula (2) or both thereof. R.sup.1 represents a hydrocarbon group comprising a monovalent alicyclic structure, or the like. R.sup.2 and R.sup.3 each independently represent a monovalent hydrocarbon group, or the like. R.sup.4 and R.sup.5 each independently represent a monovalent hydrocarbon group, or the like. R.sup.6 and R.sup.7 each independently represent a monovalent hydrocarbon group, or the like. R.sup.8 represents a monocyclic heterocyclic group together with the ester group and with the carbon atom. n is an integer of 1 to 6. R.sup.9 represents a monovalent hydrocarbon group, or the like. R.sup.10 represents a monovalent hydrocarbon group having 1 to 10 carbon atoms. R.sup.11 and R.sup.12 each independently represent a monovalent hydrocarbon group, or the like. R.sup.13 and R.sup.14 each independently represent a monovalent hydrocarbon group, or the like.

##STR00001##

The present invention relates to a thiazole-based compound, a preparation method therefor, and a use thereof. More specifically, the present invention relates to a 2,2-bis-thiazole-based compound, a preparation method therefor, and a use of 2,2-bis-thiazole-based compound a histone deacetylase inhibitor in the preparation of an antitumor medicament, a medicament for treating autoimmune diseases, a medicament for treating type II diabetes mellitus and complication thereof, or a medicament for treating neurodegenerative diseases. ##STR00001##

The present invention relates to a thiazole-based compound, a preparation method therefor, and a use thereof. More specifically, the present invention relates to a 2,2-bis-thiazole-based compound, a preparation method therefor, and a use of 2,2-bis-thiazole-based compound a histone deacetylase inhibitor in the preparation of an antitumor medicament, a medicament for treating autoimmune diseases, a medicament for treating type II diabetes mellitus and complication thereof, or a medicament for treating neurodegenerative diseases. ##STR00001##

Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, or pharmaceutically acceptable salts thereof, compositions thereof, and methods of their use. The condition or disorder mediated by HDAC comprises a neurodegenerative pathology. Accordingly, also provided is a method of treating a neurodegenerative pathology mediated by HDAC in a subject in need of such a treatment, comprising administering to the subject a therapeutically effective amount of at least one compound, or pharmaceutically acceptable salt thereof, described herein.

##STR00001##

Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, or pharmaceutically acceptable salts thereof, compositions thereof, and methods of their use. The condition or disorder mediated by HDAC comprises a neurodegenerative pathology. Accordingly, also provided is a method of treating a neurodegenerative pathology mediated by HDAC in a subject in need of such a treatment, comprising administering to the subject a therapeutically effective amount of at least one compound, or pharmaceutically acceptable salt thereof, described herein.

##STR00001##

An acid diffusion control agent includes a compound represented by a formula (1), a compound represented by a formula (2) or both thereof. R.sup.1 represents a hydrocarbon group comprising a monovalent alicyclic structure, or the like. R.sup.2 and R.sup.3 each independently represent a monovalent hydrocarbon group, or the like. R.sup.4 and R.sup.5 each independently represent a monovalent hydrocarbon group, or the like. R.sup.6 and R.sup.7 each independently represent a monovalent hydrocarbon group, or the like. R.sup.8 represents a monocyclic heterocyclic group together with the ester group and with the carbon atom. n is an integer of 1 to 6. R.sup.9 represents a monovalent hydrocarbon group, or the like. R.sup.10 represents a monovalent hydrocarbon group having 1 to 10 carbon atoms. R.sup.11 and R.sup.12 each independently represent a monovalent hydrocarbon group, or the like. R.sup.13 and R.sup.14 each independently represent a monovalent hydrocarbon group, or the like. ##STR00001##

An acid diffusion control agent includes a compound represented by a formula (1), a compound represented by a formula (2) or both thereof. R.sup.1 represents a hydrocarbon group comprising a monovalent alicyclic structure, or the like. R.sup.2 and R.sup.3 each independently represent a monovalent hydrocarbon group, or the like. R.sup.4 and R.sup.5 each independently represent a monovalent hydrocarbon group, or the like. R.sup.6 and R.sup.7 each independently represent a monovalent hydrocarbon group, or the like. R.sup.8 represents a monocyclic heterocyclic group together with the ester group and with the carbon atom. n is an integer of 1 to 6. R.sup.9 represents a monovalent hydrocarbon group, or the like. R.sup.10 represents a monovalent hydrocarbon group having 1 to 10 carbon atoms. R.sup.11 and R.sup.12 each independently represent a monovalent hydrocarbon group, or the like. R.sup.13 and R.sup.14 each independently represent a monovalent hydrocarbon group, or the like. ##STR00001##